Thomson Reuters (NASDAQ:TRI – Get Free Report) is expected to announce its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect Thomson Reuters to post earnings of $0.89 per share and revenue of $1.85 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.
Thomson Reuters (NASDAQ:TRI – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.96 by $0.03. The company had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. Thomson Reuters had a net margin of 21.22% and a return on equity of 15.82%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter last year, the business earned $0.87 EPS. On average, analysts expect Thomson Reuters to post $4.48 EPS for the current fiscal year and $5.11 EPS for the next fiscal year.
Thomson Reuters Stock Performance
TRI opened at $122.08 on Tuesday. The company has a fifty day moving average of $103.69 and a 200 day moving average of $97.64. Thomson Reuters has a fifty-two week low of $76.28 and a fifty-two week high of $163.66. The stock has a market capitalization of $52.90 billion, a price-to-earnings ratio of 29.54, a PEG ratio of 2.36 and a beta of 0.75. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.51 and a current ratio of 0.51.
Thomson Reuters Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Wednesday, August 19th were given a dividend of $0.6550 per share. The ex-dividend date was Wednesday, August 19th. This represents a $2.62 annualized dividend and a yield of 2.1%. Thomson Reuters’s dividend payout ratio (DPR) is 69.68%.
Analyst Ratings Changes
Several research analysts recently commented on TRI shares. Barclays dropped their price target on Thomson Reuters from $140.00 to $130.00 and set an “overweight” rating for the company in a research report on Tuesday, September 8th. Weiss Ratings raised shares of Thomson Reuters from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 15th. Scotiabank reiterated a “sector outperform” rating and issued a $135.00 target price on shares of Thomson Reuters in a research note on Thursday, August 6th. Canaccord Genuity Group dropped their price target on Thomson Reuters from $132.50 to $129.50 and set a “buy” rating on the stock in a research note on Thursday, October 22nd. Finally, Royal Bank Of Canada upped their target price on Thomson Reuters from $121.00 to $124.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Thomson Reuters presently has a consensus rating of “Moderate Buy” and an average target price of $127.42.
Check Out Our Latest Stock Report on TRI
Thomson Reuters Company Profile
Thomson Reuters is a global provider of information, software and technology solutions for professionals and institutions. The company serves customers in the legal, tax, accounting, audit, corporate, government, risk and compliance sectors, as well as the media industry. Its offerings combine authoritative content with workflow tools, data analytics and artificial intelligence.
Key products and services include Westlaw and Practical Law for legal research and practice management; Checkpoint and ONESOURCE for tax and accounting professionals; Confirmation for audit-related workflows; and CoCounsel, an AI-assisted legal technology platform.
Featured Stories
- Five stocks we like better than Thomson Reuters
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Thomson Reuters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thomson Reuters and related companies with MarketBeat.com's FREE daily email newsletter.
